GSE191129
Elucidating cellular states of CD8+ T cells regulating anti-tumor response using multi-omic single cell sequencing
Immune checkpoint blockade (ICB) has led to durable clinical responses in multiple cancer types; however, biomarkers that identify which patients are most likely to respond to ICB are not well defined.  Many putative biomarkers developed from a small number of samples often fail to maintain their predictive status in larger validation cohorts.  We show across multiple human malignancies and syngeneic murine tumor models that neither pre-treatment T cell receptor (TCR) clonality nor changes in clonality after ICB correlate with response.  Dissection of tumor infiltrating lymphocytes pre- and post-ICB by paired single-cell RNA sequencing and single-cell TCR sequencing reveals conserved and distinct transcriptomic features in expanded TCR clonotypes between anti-PD1 responder and non-responder murine tumor models. Overall, our results indicate a productive anti-tumor response is agnostic of TCR clonal expansion. Further, we used single-cell transcriptomics to develop a CD8+ T cell specific gene signature for a productive anti-tumor response and show the response signature to be associated with clinical outcomes to nivolumab monotherapy in CheckMate-067, a phase 3 clinical trial in metastatic melanoma.  These results highlight the value of leveraging single-cell assays to dissect heterogeneous tumors and T cell subsets and define cell-type specific transcriptomic biomarkers of ICB response. Overall design: Single cell transcriptomes were assessed in FACS sorted CD45+ immune cells, isolated from dissociated murine MC38 or CT26 tumors.  Each tumor type contained 4 treatment groups and each treatment group consisted of biological triplicates.  The four treatment groups were: Group #1) Early timepoint untreated mice (Day 6 in MC38, Day 10 in CT26), Group #2) Late timepoint untreated mice (Day 13 in MC38, Day 17 in CT26), Group #3) Mice treated with 10mg/kg isotype control antibody on Days 6 and 10 in MC38, and Days 10 and 14 in MC38 harvested at the same timepoint as group #2, Group #4)mice treated with 10 mg/kg anti-PD1 antibody on the same schedule as the isotype treatment in group #3 and harvested at the same timepoint as group #2.